Llwytho...
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disorder for which eculizumab is the only approved treatment. Life-long treatment is indicated; however, eculizumab discontinuation has been reported. Methods. Unpublished authors’ cases and published cases of eculiz...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Kidney J |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5466111/ https://ncbi.nlm.nih.gov/pubmed/28621343 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfw115 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|